APA

Shelygin Y., Krivokapic Z., Frolov S. A., Kostarev I. V., Astashov V. L., Vasiliev S. V., Lakhin A. V., Rodoman G. V., Soloviev A. O., Stoyko Y. M., Khitaryan A. G. & Nechay I. A. (20170928). Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease. : Current medical research and opinion.

Chicago

Shelygin Yuri, Krivokapic Zoran, Frolov S A, Kostarev I V, Astashov V L, Vasiliev S V, Lakhin A V, Rodoman G V, Soloviev A O, Stoyko Y M, Khitaryan A G and Nechay I A. 20170928. Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease. : Current medical research and opinion.

Harvard

Shelygin Y., Krivokapic Z., Frolov S. A., Kostarev I. V., Astashov V. L., Vasiliev S. V., Lakhin A. V., Rodoman G. V., Soloviev A. O., Stoyko Y. M., Khitaryan A. G. and Nechay I. A. (20170928). Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease. : Current medical research and opinion.

MLA

Shelygin Yuri, Krivokapic Zoran, Frolov S A, Kostarev I V, Astashov V L, Vasiliev S V, Lakhin A V, Rodoman G V, Soloviev A O, Stoyko Y M, Khitaryan A G and Nechay I A. Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease. : Current medical research and opinion. 20170928.